One-way Sensitivity Analysis for Cost-effectiveness of TB Case Finding Strategies Varying Probabilities and Costs.

aICER = Incremental Cost- Effectiveness Ratiob Ranges obtained from published literature, expert opinion, or full ranges usedc PCF+ACF becomes cost-effective at high probability of chronic cough, ICER below decision threshold of US$ 1,102.00d PCF+HCI is no longer cost effective at low probability of case detection, ICER above decision thresholde PCF+ACF becomes a cost-effective at low ACF program cost, ICER below decision thresholdOne-way Sensitivity Analysis for Cost-effectiveness of TB Case Finding Strategies Varying Probabilities and Costs.aICER即增量成本效果比（Incremental Cost-Effectiveness Ratio, ICER），其取值范围取自已发表文献、专家意见或研究中所使用的完整区间。当慢性咳嗽发生概率较高时，PCF+ACF具备成本效益，此时ICER低于1102.00美元的决策阈值。当病例检出概率较低时，PCF+HCI不再具备成本效益，此时ICER高于该决策阈值。当ACF项目成本较低时，PCF+ACF具备成本效益，此时ICER低于决策阈值。本分析为针对概率与成本可变的结核病（Tuberculosis, TB）病例发现策略的成本效果单因素敏感性分析。